<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773237</url>
  </required_header>
  <id_info>
    <org_study_id>17-001403</org_study_id>
    <nct_id>NCT03773237</nct_id>
  </id_info>
  <brief_title>Intralipid Versus SMOFlipid in HPN Patients</brief_title>
  <official_title>Randomized Prospective Trial Comparing Intralipid Versus SMOFlipid in New HPN Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will randomize all patients who are new to the Mayo Clinic HPN team to either&#xD;
      standard lipid emulsion (Intralipid) or SMOFLipid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary aim is to assess the impact to direct bilirubin.&#xD;
&#xD;
      Secondary aims will be to assess impact to other liver function studies, metabolic&#xD;
      parameters, inflammatory marker, body weight, ability to meet caloric needs through TPN, and&#xD;
      ability to obtain appropriate macronutrient composition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective Randomized Controlled</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The randomization list will be generated using http://www.randomization.com and blinded at enrollment using supplement codes. The study coordinator will hold the randomization codes and will be revealed to the investigators only after the statistical analysis is complete.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Direct Bilirubin Change is assessed</measure>
    <time_frame>At 12 weeks weeks</time_frame>
    <description>mg/dL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <condition>Intestinal Fistula</condition>
  <condition>Crohn Disease</condition>
  <condition>Intestinal Obstruction</condition>
  <arm_group>
    <arm_group_label>SMOFLipid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SMOFlipid is a lipid emulsion that contains a combination of soybean oil, medium chain triglycerides, olive oil, and fish oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IntraLipid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intralipid is a lipid emulsion that contains soybean oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SMOFLipid</intervention_name>
    <description>SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.</description>
    <arm_group_label>SMOFLipid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid</description>
    <arm_group_label>IntraLipid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly initiated Mayo Clinic HPN patient&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Anticipated duration of HPN greater than 3 months,&#xD;
&#xD;
          -  Infusion company is able to provide Smoflipid&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Failure to provide consent&#xD;
&#xD;
          -  Patients with underlying liver dysfunction (defined as liver function studies equal to&#xD;
             or more than 2 times upper limit of normal) or pathology as determined by primary&#xD;
             investigator&#xD;
&#xD;
          -  Patients with active malignancy&#xD;
&#xD;
          -  Patients who are deemed to be on HPN for less than three months&#xD;
&#xD;
          -  Patients who have previous proven addiction and dependence to alcohol/ heavy alcohol&#xD;
             AND consumption/active use reported during last 12 months.&#xD;
&#xD;
          -  Known hypersensitivity to fish, egg, soybean, or peanut protein, or to any of the&#xD;
             active ingredients or excipients in Smoflipid&#xD;
&#xD;
          -  Patients who will not be managed by the Mayo Clinic HPN team&#xD;
&#xD;
          -  Patients who have active infection (as determined by the clinician) at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients who have received Smoflipid greater than 4 weeks in the last 12 months prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  Patients who have been on TPN greater than 4 weeks in the last 12 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Enrolled in another interventional study.&#xD;
&#xD;
          -  Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides&#xD;
             more than 1,000 mg/dL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manpreet S Mundi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manpreet S Mundi, MD</last_name>
    <phone>507-284-4080</phone>
    <email>Mundi.Manpreet@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vishakantha (Vishu) Murthy, PhD</last_name>
    <phone>507-255-8112</phone>
    <email>Murthy.Vishakantha@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manpreet Mundi, MD</last_name>
      <phone>507-284-4080</phone>
      <email>Mundi.Manpreet@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vishakantha Murthy, PhD</last_name>
      <phone>507-255-8112</phone>
      <email>Murthy.Vishakantha@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Manpreet S. Mundi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SMOF</keyword>
  <keyword>Intralipid</keyword>
  <keyword>Mixed oil emulsion</keyword>
  <keyword>Intestinal failure</keyword>
  <keyword>HPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Intestinal Obstruction</mesh_term>
    <mesh_term>Intestinal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
    <mesh_term>SMOFlipid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

